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The cell-death programme, apoptosis, is well established as a tumour suppres-
sor mechanism. Paradoxically, high levels of apoptosis in tumours are closely
coupled with poor prognosis. Indeed, where it has been studied, cell loss is a
striking feature of high-grade cancers, illustrating the importance of consider-
ing malignant disease as an imbalance between cell gain and cell loss that
favours cell gain rather than as a unidirectional disorder of cell gain alone.
In addition to orchestrating cell loss, apoptosis can signal regenerative
responses—for example compensatory proliferation—in neighbouring cells.
Accumulating evidence suggests that normal tissue repair and regenerative
processes are hijacked in the malignant tissue microenvironment such that
cancer may be likened to a ‘wound that fails to stop repairing’. We have pro-
posed that a critical requirement for the successful growth, progression and
re-growth of malignant tumours is a complex milieu, conceptually termed
the ‘onco-regenerative niche’, which is composed, in addition to transformed
neoplastic cells, of a network of normal cells and factors activated as if in
tissue repair and regeneration. Our work is based around the hypothesis
that tumour cell apoptosis, macrophage activation and endothelial activation
are key, interlinked elements of the onco-regenerative niche and that apoptotic
tumour cell–derived extracellular vesicles provide critical intercellular com-
munication vehicles of the niche. In aggressive B-cell lymphoma, tumour cell
apoptosis promotes both angiogenesis and the accumulation of pro-tumour
macrophages in the lymphoma microenvironment. Furthermore, apoptotic
lymphoma-derived extracellular vesicles have potent pro-tumour potential.
These findings have important implications for the roles of apoptosis in
regulation of malignant diseases and for the efficacy of apoptosis-inducing
anti-cancer therapies.
This article is part of the discussion meeting issue ‘Extracellular vesicles
and the tumour microenvironment’.1. Introduction: apoptosis and the tumour microenvironment
Apoptosis, the most widely studied cell death programme, serves many functions
in normal physiological processes, ranging from organ sculpting during embry-
ogenesis to adult tissue homeostasis. In disease, perhaps its highest renown is
as a tumour suppressor: to remove cells carrying genetic aberrations including
those with oncogenic potential. In this respect, the capacity to avoid apoptosis
has long been accepted as an important acquired characteristic of malignant
and pre-malignant cells [1]. Consequently, anti-apoptotic pathways have been
identified as important routes to malignant disease. Indeed, the prototypic anti-
apoptotic gene, BCL-2, provided the first example of a new class of oncogenes
that promote cell survival rather than cell proliferation [2]. Furthermore, apopto-
sis induction in tumour cells is a common mode of action both of pharmaceutical
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which, as we will discuss, lends itself to oncogenic, as well as
anti-oncogenic, processes.
While it is intuitive that cell death constrains cancer, which
is largely viewed as a range of diseases in which unconstrained
proliferation occurs, certain characteristics of malignant dis-
ease are perhaps counterintuitive, at least when considered
superficially. Firstly, cell loss is a substantial component of
aggressive malignancies. Thus, where constituent cell popu-
lation growth kinetics have been compared to the volumetric
growth of tumours, it has been concluded that massive
cell loss commonly occurs in diverse tumour types, largely
through cell death [5,6]. Second, high proliferation indices are
commonly accompanied by high apoptosis indices in aggres-
sive tumours of various types [6–14]. High apoptosis indices
are also reflected by high incidences of activated effector
caspases—cysteinyl proteases that execute the cell death
programme—in multiple malignancies (see, for example
[15–19]). Strong coupling between rapid proliferation and
apoptosis is common in both normal and malignant tissues.
Amidst other factors, this is likely to stem not only from com-
petition for limited nutrients but also from proliferating cells
being ‘primed’ for apoptosis as described seminally as a conse-
quence of the activity of the proto-oncogene product c-Myc [20]
which is an obligate driver of both proliferation and apoptosis
[21]. The intrinsic, mitochondrial pathway of apoptosis is
activated in response to stress signals, including nutrient
stress, chemotherapy and radiation. The critical point of no
return in this pathway is mitochondrial outer membrane per-
meability (MOMP), which allows cytochrome c to be released
into the cytosol to form a crucial component of the apopto-
sis-initiating protein complex known as the apoptosome [22].
MOMP is induced by pro-apoptotic Bcl-2 family members,
Bax and Bak, and inhibited by anti-apoptotic members Bcl-2,
Bcl-xL and Mcl-1. Induction of MOMP requires inhibition of
the latter proteins by the so-called BH3-only Bcl-2 family
relatives, notably Bid and Bim. Recently, c-Myc has been
shown to be an important regulator of apoptosis priming
through its ability to promote the expression of the pro-
apoptosis Bcl-2 family proteins, Bax, Bid and Bim [23], thereby
controlling intrinsic (mitochondrial) apoptosis thresholding.
Conditions of stress, which are characteristic of rapidly grow-
ing tumours, seem likely to be important for the constitutive
apoptosis of aggressive cancers.
Therefore, far from being free from cell death, aggressive
malignant disease represents an imbalance between cell birth
and cell death such that the former dominates and net popu-
lation expansion occurs (figure 1). The objective of therapy is
to reverse this balance so that cell deletion is the net result
with consequent tumour destruction (figure 1). However, the
presence of apoptosis within tumour populations does not
simply signify cell loss, for apoptosis offers more than mere
cell deletion. Indeed, apoptosis holds important consequences
for the tissue in which it occurs, not least in terms of the
responses it can engender in its immediate or near vicinity.
The capacity of apoptosis to modulate immune and inflamma-
tory responses and to trigger tissue repair and regeneration has
important implications for its oncogenic potential.
Here the ‘hidden’ pro-tumour properties of apoptosis are
considered, both from the perspectives of emerging evidence,
and from a speculative standpoint. The concept of our recently
proposed, apoptosis-driven ‘onco-regenerative niche’ (ORN)
[6] will be developed with particular reference to the roles ofapoptosis-responsive tumour-associated macrophages (TAM)
and of apoptotic tumour cell–derived extracellular vesicles
(Apo-EV) (figure 2).2. Tissue repair responses to apoptosis:
phagocytic and anti-inflammatory effects
Classically, apoptosis contrasts with non-programmed, necro-
tic cell death in failing to incite inflammatory responses and
providing tolerogenic signals to the adaptive immune system
[24] (although, under certain circumstances, apoptosis can be
immunogenic, and necrosis can also be programmed—see
[25–27] for recent reviews). In fact, the best-known responses to
apoptotic cells are described as anti-inflammatory, character-
ized by the production of anti-inflammatory mediators, such
as TGF-b1, IL-10 and PGE2, which are associated with suppres-
sion or resolution of inflammatory responses [24,28,29]. The
non-phlogistic nature of apoptosis is reflected in the absence
of inflammatory effects of the process during normal physi-
ology. For example, in the thymus, an organ in which the
vast majority of the cells it produces undergo apoptosis,
the process is histologically virtually invisible. This illustrates
the rapidity with which apoptotic cells are removed from
histological sight and this occurs as a consequence of phago-
cytosis that is dependent on Rac-1 signalling [13,30]. The
phagocytes of apoptotic cells fall into two categories: (i) so-
called non-professional phagocytes, neighbouring cells of
diverse lineages, including fibroblasts, endothelial cells, epi-
thelial cells and many others that are not otherwise overtly
phagocytic, and (ii) professional phagocytes, notably macro-
phages, be they resident tissue macrophages or macrophages
recruited to sites of high-rate apoptosis such as resolving
inflammation [13,31–35]. In the latter context, which may
occur as a result of tissue damage—with or without infec-
tion—macrophage accumulation is an essential part of the
inflammatory response that is required for tissue repair.
Furthermore, macrophages are key cellular players in
anti-inflammatory responses to apoptotic cells although non-
professional phagocytes also make important contributions
relative to tissue context. Indeed, recent studies have indicated
that, in lung inflammation, phagocytic clearance of apoptotic
lung epithelial cells is mediated by their viable epithelial neigh-
bours, which are triggered to release anti-inflammatory
cytokines via Rac-1-dependent signalling [36]. Intriguingly,
polymorphonuclear leucocytes, which form the major cellular
arm of the acute inflammatory response to infection or necro-
sis, are professional phagocytes par excellence, but they are
rarely involved in phagocytic clearance of apoptotic cells [37].
Apoptotic cells secrete chemotactic ‘find-me’ signals, including
lysophosphatidyl choline [38], sphingosine-1-phosphate (S1P)
[39], fractalkine [40], and nucleotides (ATP and UTP) [41],
along with ‘keep-out’ signals such as lactoferrin [37,42] in
order to ensure selective attraction of mononuclear phagocytes.
Hence, both in normal tissues and in tumours, apoptotic cells
are readily encountered histologically at sites of apoptosis in
association with macrophages.
The phagocytes of apoptotic cells deploy a multitude of
receptors in order to engage with, and respond to, apoptotic
cells effectively and non-phlogistically. These molecular mech-
anisms have been reviewed in detail recently and constitute
two main categories according to their dependence on phos-
phatidylserine (PS), a seemingly universal lipid ‘eat-me’
Figure 1. Imbalances in proliferation and death in cell populations of relevance to cancer. (1) Balanced expansion (left) and death (right; here illustrated by apoptosis) of
cells within a population—as occurs in homeostasis—results neither in net growth, nor net death, and the population remains at a set size. (2) Imbalance caused by
proliferation outpacing apoptosis results in net population expansion (green arrow) as occurs in cancer. Direct or indirect signals from apoptotic cells may feed forward into
the population expansion side, for example to promote tumour growth (dashed grey arrow, A). (3) Net reduction of cell populations occurs when apoptosis outpaces
proliferation (red arrow), for example as a result of an apoptosis-inducing anti-cancer therapy. Mitogenic signals emanating from apoptotic cells (dashed grey arrow, B)
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vation of a PS scramblase, Xkr8, in the plasma membrane by
the effector caspases, caspase-3 and -7 together with the inacti-
vation of flippase activities by the same caspases [43,44].
Phagocyte integral membrane receptors that interact directly
with apoptotic cell surface-exposed PS comprise BAI1, TIM4,
Stabilin 2, TLT2 and RAGE. Additional, secreted PS receptors
that essentially opsonize apoptotic cells include (i) MFG-E8,
which bridges to the phagocyte integrins, avb3 and avb5, and
(ii) the Mertk ligands, Gas6 and Protein S (reviewed recently
by [35]). Mertk is a receptor tyrosine kinase that is active
in tethering and engulfing apoptotic cells and in anti-
inflammatory signalling responses of phagocytes toward
them [45–47]. It is noteworthy that PS exposure is not sufficient
for the phagocytic clearance of apoptotic cells [48]. It is known
that further moieties, which, in addition to lipid, include
carbohydrate, protein and nucleic acid molecular classes, are
exposed at the surface of apoptotic cells. Enzymes that
become activated at the plasma membrane are important for
the exposure of ligands other than PS that are functional in
clearance responses. For example, activation of neuraminidase
at apoptotic cell surfaces promotes engulfment [49]. Further-
more, disabled ‘don’t-eat-me’ signalling components such as
CD31 [50] and CD47 [51] at apoptotic cell surfaces also serve
significant roles in facilitating phagocytosis. Indeed, blockadeof CD47 suppresses its ability to ligate the inhibitory phagocyte
receptor SIRPa and is sufficient to activate engulfment of
viable cells independently of PS exposure [52].
The complexity of the pathways available for the engulfment
of apoptotic cells may reflect specific axes being needed to engulf
specific types of apoptotic cell or those in particular phases of
apoptosis—essentially first-line and back-up mechanisms, illus-
trating the importance of the speed and efficiency of the
clearance response. Thus, defects in certain of the clearance
pathways—those involving C1q, MFG-E8 and Mertk—cause
persistence of apoptotic cells associated with autoimmune,
SLE-like disease sequelae [53–55]. By contrast, defects in other
pathways such as CD14 and MBL result in persistence of apop-
totic cells in the absence of autoimmune disease characteristics
[56,57]. These results are consistent with the view that the
former pathways signal anti-inflammatory and tolerogenic
responses while the latter are mainly involved in tethering of
apoptotic cells to phagocytes, their deficiency leaving anti-
inflammatory signalling intact. Both in tissue repair and in
homeostatic clearance of apoptotic cells, the anti-inflammatory
microenvironment prevents unwanted inflammation and auto-
immunity. In tissue repair, efficiency in the PS-dependent
pathways involving MFG-E8 and Mertk may be essential [58,59].
Phagocytes of different types, including different acti-
vation states of macrophages, may also favour deployment
Figure 2. Basic concept of an apoptosis-driven onco-regenerative niche. Apop-
tosis is induced in tumour cells (T) when pro-apoptosis signalling predominates
(e.g. as a consequence of nutrient limitation, anti-tumour immunity or therapy;
represented by red arrows, top left). Apoptotic cells generate pro-tumour
responses (bold green arrows) in tumour cells and tumour stromal cells such
as tumour-associated macrophages (TAM) which also interact with each other
(double-headed black arrow). Apoptosis-driven reparatory and immunomodula-
tory responses of cells in the tumour microenvironment are generated through
direct intercellular contact or via release of soluble factors (Secretome) or extra-
cellular vesicles (Apo-EV) from apoptotic cells. It is proposed that the complex
network of cells and factors thus generated constitutes the onco-regenerative
niche (ORN). The driver of the ORN may be caused by apoptosis of stromal
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anti-inflammatory effects. In this way, specific receptor
usage may be coupled to particular tissue responses such
as the promotion of cell survival, proliferation, angiogenesis
or matrix remodelling, among others. These cellular pro-
cesses, which are not limited to phagocytes, are likely to be
highly important in tissue repair and in regeneration and,
as discussed below, may constitute particularly important
responses to apoptosis in tumours that promote cancer evol-
ution and progression. Cancer has often been likened to ‘a
wound that fails to heal’ [60], bearing many of the hallmarks
of chronic inflammation. It is perhaps more accurate to com-
pare cancer to ‘a wound that fails to stop repairing’ [6]. In this
analogy, continued apoptosis and the consequent clearance
of apoptotic cells in the tumour tissue exemplifies protracted
resolution of inflammation. This theme is continued below
in consideration of the composition of the ORN.3. Tissue regenerative responses to apoptosis
Extending the viewpoint that apoptosis represents more than
mere programmed cell deletion and cell removal, bourgeon-
ing evidence indicates that the apoptosis machinery can
also influence tissue regeneration. This makes teleological
sense since, according to circumstances, replacement of
deleted cells may be required. It should also be noted, by con-
trast, that apoptosis can also induce further apoptosis in
neighbouring cells. This phenomenon of ‘apoptosis-induced
apoptosis’ (AiA) was first defined during development of
the fruit fly, Drosophila melanogaster, and was subsequently
found to be responsible for the synchronous cell death of
hair follicle cells during catagen in mice. In both cases, AiA
was mediated by TNF produced by the apoptotic cells [61].
Regenerative responses associated with apoptosis, often
referred to as ‘apoptosis-induced proliferation’ (AiP) or‘compensatory proliferation’, have been described in various
models from mammals to lowly multicellular animals like
Hydra and planarian flatworms. A striking example is the
regenerative response which follows wounding of Hydra, a
freshwater metazoan which is anatomically simple, essen-
tially comprising a tubular body at one end of which is a
foot specialized for attachment to its substratum and at the
other extremity a head structure specialized for feeding and
excretion. Transverse bisection of this animal in the midline
of the body results in both head and foot regeneration.
Head regeneration requires the Wnt-b-catenin pathway and
is initiated by caspase activation and Wnt3 release from
apoptotic interstitial cells. This causes nuclear translocation
of b-catenin, synchronous proliferation of interstitial cells
and upregulation of Wnt3 in epithelial cells, culminating in
head regeneration. Notably, apoptosis is necessary and suffi-
cient to produce the Wnt3 required for head regeneration
following midline amputation and apoptosis is even sufficient
to induce ectopic head regeneration [62].
The zone of proliferating cells adjacent to the apoptotic
zone in regenerating Hydra is reminiscent of the proliferating
zones characteristic of the blastemas of regenerating limbs
(although the role of apoptosis or caspase activation in
establishing these has not been defined, cf [63]) and of the
compensatory proliferation that is observed associated with
apoptosis in Drosophila imaginal discs. In Drosophila, the
compensatory proliferation that occurs in imaginal disc com-
partments neighbouring those in which apoptosis is induced,
is also regulated via Wnt-b-catenin, as well as BMP and Hh, sig-
nalling [64–67]. Conserved signalling pathways associated
with regeneration coupled to apoptosis have been observed
in mammalian systems too. Hh signalling, for example, has
been shown to link apoptosis of hepatocytes with compensa-
tory proliferation of liver progenitors and myofibroblasts [68].
Liver regeneration, along with skin wound healing, has been
found to be dependent optimally on the activity of the effector
caspases, caspase-3 and -7. Intriguingly, downstream regenera-
tive responses to effector caspase activity led to production
of PGE2, which, in addition to its modulatory effects on
inflammation, promotes progenitor cell proliferation [69]
and activates Wnt signalling [70]. PGE2 has also been reported
to promote tumour repopulation (post irradiation) and
angiogenesis downstream of caspase-3 activation and apopto-
sis in murine tumour models including xenografts of human
tumour lines [15,71]. These studies point to PGE2 as a
common pro-regeneration and pro-tumour mediator produced
by apoptotic cells—both transformed tumour cells and tumour
stromal cells—as a consequence of effector caspase activation.
However, since PGE2 is also a well-known anti-inflammatory
mediator produced by macrophages that engulf apoptotic
cells [29], it is probable that TAM also contribute to this mech-
anism. Intracellular signalling molecules in cells undergoing
apoptosis that are associated with their proliferation-inducing
activity in various animal models include PKCd, Akt, MAPK
and JNK [63,66,72–74]; in Drosophila, diverse additional path-
ways have also been implicated, including p53, Notch, EGF
and Hippo (reviewed in [75]).4. The concept of the onco-regenerative niche
The importance of tissue niches, otherwise known as microen-
vironments, is well known in regeneration and cancer. Paget’s
Figure 3. Pro-tumour macrophages in aggressive, starry-sky non-Hodgkin lymphoma (NHL). In starry-sky lymphoma, tumour-associated macrophages (SS-TAM, e.g.
circled left) are observed actively engaged in the clearance of apoptotic cells. Note also the high rate of proliferation in these tumours as illustrated by the frequent
mitotic figures (black arrows). In situ transcriptomics of SS-TAM shows that they upregulate numerous genes involved in responses to apoptotic cells and in pro-
tumour and reparatory responses, providing strong evidence that apoptosis may drive numerous pro-tumour macrophage activities such as promoting cell growth,
angiogenesis, matrix degradation and metastasis while at the same time inhibiting anti-tumour immunity. SS-TAM are capable of proliferating in situ as shown by
the filled white arrow (lower centre panel). This shows an example of a mouse macrophage in a starry sky human NHL xenograft co-labelled for macrophage F4/80
(green fluorescence) and the proliferation marker, Ki67 (red). Non-proliferating macrophages are also present (e.g. open white arrow). Faint red signal in the
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anisms surrounding the ability of certain tumour cells (the
‘seed’) to metastasize to certain tissues (the ‘soil’) [76], provides
a stimulating conceptual foundation for the evolution of
knowledge of tumour microenvironments, their association
with tissue repair and regeneration and their significance in
post-therapeutic relapse. We recently proposed the concept of
the ‘onco-regenerative niche’ (ORN) [6], suggesting that cell
death in tumours provides a central driving force in shaping
the tumour microenvironment by orchestrating a series of
interconnected cellular responses and extracellular modifi-
cations that promote tumour growth, progression and
relapse. The ORN, its constituent key cells, molecules and
activities, is a ‘skeletal’ concept at present, serving as a frame-
work for improving our understanding of the broad
implications of cell death in tumours, be it constitutive as
part of cancer pathogenesis, or induced as a consequence of
therapy. The association of apoptosis and apoptotic cell clear-
ance with wound healing, tissue regeneration and aggressive
malignant disease provides the initial basis for developing
the ORN concept. Here, TAM (that are activated by apoptotic
cells) and extracellular vesicles (EV, that are produced by apop-
totic cells), are proposed as two important ORN components
(figure 2).5. Roles of macrophages
Although it is well known that the macrophage is a constituent
of the innate immune system and has anti-tumour capability, in
most (though by no means all) tumours, the macrophage com-
ponent tends to support the growth of established tumours andfacilitates their progression and metastasis [6,77–79]. The
tumour-supportive activity of TAM stems from signals arising
from the tumour that effectively polarize the functional status
of the macrophages towards a reparatory phenotype, often
referred to as ‘M2-like’, which starkly contrasts with the M1
or M1-like phenotype of macrophages that mediate anti-
tumour effector functions. The tumour-supportive properties
of TAM, which have established roles in promoting cell
growth, angiogenesis and matrix remodelling, while at the
same time suppressing anti-tumour immune responses, are
reminiscent of the properties of macrophages that are driven
by their interaction with apoptotic cells [6,13]. In fact, apoptotic
cells are drivers of M2-like activation of macrophages [80] and
impose dominant effects on M1 macrophages, potently sup-
pressing their anti-tumour activity [81]. The ‘M1-suppressive’
property of apoptosis has serious implications for tumour
repopulation post therapy and suggests that the very apoptosis
of tumour cells that is triggered by anti-tumour, M1-like macro-
phages could lead to repolarization of the latter to become
M2-like, tumour supportive cells. This isa particularly important
consideration if TAM repolarization from pro- to anti-tumour is
to be useful as an effective anti-tumour immune therapy.
Recent work from our laboratory has shown that the
accumulation and activation of macrophages in aggressive,
B-cell non-Hodgkin lymphoma (NHL) is controlled by constitu-
tive apoptosis in the tumourcells [14]. In B-cell NHL that display
a ‘starry-sky’ histological appearance (figure 3) the ‘stars’ repre-
senting the accumulating TAM, set in a ‘sky’ of tumour cells,
prototypically the tumour architecture of Burkitt’s lymphoma,
BL), the frequent TAM are clearly engaged in interaction with
numerous apoptotic tumour cells that are generated constitu-
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by Bcl-2 or Bcl-xL and tumour growth and angiogenesis were
constrained in parallel. Gene expression profiling of the TAM
in situ clearly demonstrated their potential for supporting
tumour growth, angiogenesis, matrix degradation and for sup-
pressing anti-tumour immunity (figure 3). Profiled starry-sky
TAM also highly expressed genes associated with known apop-
totic cell clearance pathways, such as LRP1, MERTK, AXL (a
close relative of MERTK), GAS6, CD36 and LGALS3 (the gene
encoding galectin-3). Studies of the relative significance of
these pathways in supporting tumour growth are in progress.
Notably, galectin-3 deficiency profoundly inhibits tumour
growth in a murine syngeneic transplantation model of aggres-
sive starry-sky NHL [81].
The in situ global gene expression profile of starry-sky TAM
illustrates the likelihood that multiple tumour-supportive sig-
nalling pathways are activated in these cells as a consequence
of interaction with apoptotic cells in the tumour micro-
environment, particularly apoptotic tumour cells but possibly
apoptotic stromal cells too. Little is yet known about the
cross-talk between the various ligand-receptor pathways
involved in the interactions between macrophages and apopto-
tic cells and their relevance to the ORN, although it is notable
that find-me signals can promote engulfment. For example,
fractalkine (CX3CL1) stimulates MFG-E8 production and
enhances apoptotic cell clearance [82], while S1P activates a
novel erythropoietin-mediated phagocytic and tolerogenic
pathway [83]. These observations illustrate a potentially impor-
tant principle—that mononuclear phagocytes may become pre-
programmed to activate specific phagocytic, anti-inflammatory
and possible additional responses in preparation for key func-
tional activities in the locale of the apoptotic cell. This may be
important in harnessing particular phagocyte responses
during recruitment to the ORN. Furthermore, opsonins of
apoptotic cells and anti-inflammatory mediators produced
either in response to apoptosis, or directly by apoptotic cells
may act to facilitate mononuclear phagocyte accumulation
and reparative activity. Thus, the lung surfactant protein,
SP-A acts as achemoattractant foralveolar macrophages andpro-
motes their engulfment of apoptotic cells [84,85]. Furthermore,
TGF-b, which is produced by macrophages as a consequence
of apoptotic cell clearance, or even directly by apoptotic cells
themselves [24,86], activates chemotaxis of monocytes, stimu-
lating their ability to induce fibroblast growth [87]. Similarly,
IL-10—which can also be produced in response to apoptotic
cells or again by apoptotic cells themselves [28,88]—promotes
both apoptotic cell clearance and survival, thereby facilitating
growth of malignant B cells [89]. As we have demonstrated
recently, apoptosis promotes macrophage accumulation in
NHL, which seems likely to result from a combination of
recruitment and proliferation in situ [14] (figure 3). However,
the extent to which apoptotic cell-activated resident tissue
macrophages and apoptotic cell-recruited macrophages
deploy common or differential signalling pathways in response
to apoptosis has not been defined.6. Roles of apoptotic cell – derived extracellular
vesicles
Intercellular communication pathways provide critical networks
in the tumour microenvironment including, conceptually, the
ORN. Apoptotic cells communicate with their neighbours,whether phagocytic or non-phagocytic, (i) by direct cell-to-cell
contact, (ii) by release of bioactive molecules into the extra-
cellular milieu (the apoptotic ‘secretome’), and (iii) through
production of membrane-bound sub-cellular vesicles, including
apoptotic bodies (figure 2). Apoptotic bodies are difficult to
define and the term has been used in various descriptions, ran-
ging from the remains of the dead cell body to the ‘blebs’ that
are released from the dying cell. Often, apoptotic bodies are arbi-
trarily separated from other EV released from apoptotic cells
(hereafter referred to as Apo-EV) on the basis of size, with
Apo-EV being less than 1 micron and apoptotic bodies ranging
from 1 to several microns in diameter [90]. However it is well
accepted that size is unreliable in functionally defining different
EV types and EV heterogeneity remains a most important chal-
lenge in EV biology. Cargoes associated with populations of
Apo-EV and apoptotic bodies have been described and, like
other EVs, include integral plasma membrane proteins,
enzyme systems and RNAs, with apoptotic bodies also harbour-
ing organelles and nuclear components including DNA and
histones [91–94]. Therefore, subcellular vesicles produced by
apoptosis in the tumour microenvironment offer much potential
to modulate the ORN.
Significantly, Apo-EV from endothelial cells have been
shown to be capable of immunomodulatory activity [93]. Fur-
thermore, apoptotic bodies are known to be able to transfer
genomic DNA, including oncogenes, to phagocytes, although
current knowledge indicates that gene expression arising from
such transfer is only short-lived because of p53-dependent
DNA damage responses in recipient cells [95–97]. Since
mutant oncogenes characteristic of tumour cells can also be
found in neighbouring tumour stromal cells [98], it seems
plausible that horizontal gene transfer may occur via apoptosis
in the ORN, thereby providing a novel route to transient or
long-lived stromal cell activation. Whether or not this is the
case, further studies are warranted to determine the extent to
which apoptotic cell–derived vesicles drive tumour growth
and progression, especially since EV from non-apoptotic
sources have proven capacity in oncogenic activities as well as
in tissue repair and regeneration [99–101].7. Conclusion and future perspectives
Apoptosis, fundamentally important in physiological and thera-
peutic anti-tumour activities, can also engender pro-tumour
effects through its impact on tumour cells, immune cells and
stromal cells of the tumour microenvironment. It seems likely
that the apoptosis programme will also prove to be able to oper-
ate systemically. Its pro-tumour properties are closely tied into
the tissue repair and regenerative responses that are dysregu-
lated in malignant disease but the underlying molecular
mechanisms are, as yet, only poorly understood. Given the indi-
cations that pathway usage in translating apoptosis to
compensatory proliferation is evolutionarily conserved from
Hydra to mammals, we hypothesize that conserved tissue
repair and regenerative molecular pathways driven by cell
death are hijacked in diverse cancer types. There are many chal-
lenges in testing this hypothesis, and future research will need to
address several fundamental questions. Critically, how
are responses to apoptosis differentially regulated? For example,
what are the signals that permit discrimination between apopto-
sis-induced proliferation, AiP, and null responses to apoptosis




 on November 29, 2017http://rstb.royalsocietypublishing.org/Downloaded from cases at least, include apoptosis-induced survival of neighbours
[102]? What are the relative roles of molecular interactions
achieved via intercellular contact or transfer through the
secretome of apoptotic cells or via apoptotic EV? What is
the relative importance of apoptosis of tumour cells versus
apoptosis of stromal cells and immune cells, including cancer-
associated fibroblasts, mesenchymal stromal cells and TAM?
To what extent does this differ between tumour types? In
order to define clear roles for apoptosis, it will be crucial to dis-
criminate between cell stress (i.e. molecular mechanisms that can
induce apoptosis) and apoptosis per se. It will also be important
to discriminate mechanisms that specifically require apoptosis
from those that are dependent on non-apoptotic roles of the
apoptosis machinery such as caspases, which are known to
perform diverse non-apoptotic functions. Finally, do other
manifestations of regulated cell death such as necroptosis,
autophagy and ferroptosis contribute to the ORN?It is our hope that the concept of the ORN will provide a
platform from which to answer these and other important
questions concerning the ways in which cell death can
impinge on the tumour microenvironment. Because both con-
stitutive and therapy-induced cell death processes are so
fundamental in cancer biology and treatment, knowledge
gains in this area hold much promise for future develop-
ments in improving the long-term treatment of a broad
range of cancers.Data accessibility. This article has no additional data.
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